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Abstract
To date, the majority of HIV-1 phenotypic resistance testing has been performed with subtype B virus backbones (e.g.
HXB2). However, the relevance of using this backbone to determine resistance in non-subtype B HIV-1 viruses still needs to
be assessed. From 114 HIV-1 subtype C clinical samples (36 ARV-naı ¨ve, 78 ARV-exposed), pol amplicons were produced and
analyzed for phenotypic resistance using both a subtype B- and C-backbone in which the pol fragment was deleted.
Phenotypic resistance was assessed in resulting recombinant virus stocks (RVS) for a series of antiretroviral drugs (ARV’s) and
expressed as fold change (FC), yielding 1660 FC comparisons. These AntivirogramH derived FC values were categorized as
having resistant or sensitive susceptibility based on biological cut-off values (BCOs). The concordance between resistance
calls obtained for the same clinical sample but derived from two different backbones (i.e. B and C) accounted for 86.1%
(1429/1660) of the FC comparisons. However, when taking the assay variability into account, 95.8% (1590/1660) of the
phenotypic data could be considered as being concordant with respect to their resistance call. No difference in the capacity
to detect resistance associated with M184V, K103N and V106M mutations was noted between the two backbones. The
following was concluded: (i) A high level of concordance was shown between the two backbone phenotypic resistance
profiles; (ii) Assay variability is largely responsible for discordant results (i.e. for FC values close to BCO); (iii) Confidence
intervals should be given around the BCO’s, when assessing resistance in HIV-1 subtype C; (iv) No systematic resistance
under- or overcalling of subtype C amplicons in the B-backbone was observed; (v) Virus backbone subtype sequence
variability outside the pol region does not contribute to phenotypic FC values. In conclusion the HXB2 virus backbone
remains an acceptable vector for phenotyping HIV-1 subtype C pol amplicons.
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Introduction
Within the past decade, access to antiretroviral therapy (ART)
for HIV-1 infection has increased exponentially in low- and
middle-income countries. More than six million people were
receiving highly active antiretroviral therapy (HAART) in these
countries at the end of 2010, as compared to just 400 000 at the
end of 2003 [1]. However, a major hurdle to sustainable,
successful ART is the inevitable emergence of HIV-1 drug
resistance. In addition, inadequate resources and health care
infrastructure in these regions, as well as the introduction of ART,
can create conditions for the accelerated development of HIV-1
resistance to antiretrovirals (ARVs) [2], further compromising the
patients’ future treatment options. Hunt et al. (2011) showed that
an average of 34% of South African children under the age of 24
months had developed non-nucleoside reverse transcriptase
inhibitor (NNRTI) resistance, in particular the Y181C mutation,
when they were previously exposed to single dose nevirapine
(sdNVP) [3].
HIV-1 transmitted drug resistance mutations (TDRMs) were
evaluated in recently infected individuals from some East and
Southern African countries, and showed a 5.0 and 5.6%
prevalence respectively [4], [5]. Hamers et al. (2010) [6] found
that HIV-1 drug resistance mutations were present in 6% of
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34708patients initiating ART in Lusaka, Zambia. Levels of transmitted
resistance have been shown to be 8.6% in Kampala, Uganda [7].
In light of these findings, focus should be placed on optimal
frequency of both viral load testing and appropriate antiretroviral
drug resistance testing.
HIV-1 ARV drug resistance is usually measured by genotypic
testing. It still remains an expensive test and is not yet an option for
individual patient management in resource poor settings, but is a
vital tool for resistance surveillance of large-scale HIV treatment
programs. During genotypic resistance testing, the nucleotide
sequence of specific HIV-1 genes, which are responsible for ARV
drug resistance, are determined and fed into a predictive
algorithm, describing the susceptibility to a range of ARVs. The
pol region is sequenced when the drug therapies of the patient
contain nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), and protease
inhibitors (PIs). Most of the algorithms for predicting drug
resistance are based on data derived from in vivo (clinical outcome
data) or in vitro phenotypic testing of subtype B virus (vircoHTYPE
and PhenoSenseH GT).
However, HIV-1 subtype C accounts for over 48% of all global
infections, and is the predominant circulating subtype amongst the
heterosexual population in sub-Saharan Africa [8]. The preva-
lence of HIV-1 subtype C resistance amongst patients failing first-
line HAART has been shown to be 82% in the South African
public sector [9] and in a study by Murphy et al. 2010 [10], it was
noted that 87% of patients on HAART for 12 months had
developed at least one resistance mutation.
In contrast to HIV-1 genotype resistance testing, phenotyping is
an in vitro assay, which measures the ability of a virus to replicate in
the presence of a drug. Currently, most available phenotyping
assays are based on recombining patient-derived sequences into a
subtype B backbone deleted for the corresponding patient
sequences. HIV-1 phenotyping is considered to be the gold
standard in resistance testing, although it is has only been
performed, using subtype B backbones. Phenotyping is not a tool
that could be adapted to resource limited settings due to its high
cost, infrastructural requirements, and technical skill needed. Until
recently, it remained, however, unclear whether a recombinant
virus assay using a subtype B backbone would correctly measure
drug resistance when the patient-derived sequences are of subtype
C. The AntivirogramH assay [11] recombines patient-derived PR
and RT sequences into an HIV-1 subtype B (HXB2) backbone
deleted for these sequences [12]. Nauwelaers et al. (2011) [13]
constructed an HIV-1 subtype C-backbone within the Antiviro-
gramH assay setting, and tested eight subtype C samples on a
clonal level within both an HIV-1 subtype B- and C- backbone.
Resistance profiles generated were similar in both backbones. The
present study is an extension of the work by Nauwelaers et al.
(2011), comparing population-based phenotypic HIV-1 drug
resistance profiles of subtype C gag-protease-reverse transcriptase
(GPRT) sequences generated using a subtype B- and C-backbone.
The aim was to assess whether an HIV-1 subtype B- backbone
could be used with a high level of confidence to phenotype subtype
C samples.
Materials and Methods
1. Ethics Statement
Ethical clearance for this study was obtained and approved for
by the Human Research Ethics Committee (HREC) at the
University of the Witwatersrand (Clearance Number M090688),
and for the PASER-M cohort from the Academic Medical Center
Institutional Review Board and the University of Zambia
Research Ethics Committee. Informed consent was obtained for
samples from the PASER-M cohort, but not for those from the
University of the Witwatersrand, as it was not required for the
ethical approval obtained from the HREC. The data derived from
this work was for research and development purposes and for
method validation only. According to HREC policies, for this type
of study, these specimens did not require patient enrollment or
informed consent, and a waiver was hence granted.
2. Patient samples used in this study
Plasma samples received for routine population-based HIV-1
drug resistance genotyping were analyzed with the genotyping
assay described by Wallis et al. (2010) [14]. A total of 265 samples
were used for further phenotypic testing. Two hundred and fifteen
(215) samples were obtained from treatment-experienced patients
attending clinics in the public sector in Johannesburg, South
Africa, and selected specifically for the presence of HIV-1 ARV
drug resistance. Fifty (50) treatment-naı ¨ve samples were selected
from the PASER-M cohort [15], based on available genotypic
information.
3. Viral RNA Extraction
Viral RNA was isolated from all patient plasma samples using
the MagNA pure LC Total Nucleic Acid Isolation Kit (Roche,
Mannheim, Germany) with a sample input of 200 ml, and a 50 ml
elution volume, as per manufacturer’s instructions. Viral RNA
from recombinant virus stocks (RVS) was extracted using the
QIAamp Virus BioRobot MDx kit (Qiagen, Belgium) or the
NucliSENS easyMAG (bioMe ´rieux Inc, Belgium), starting with an
input volume of 600 ml and eluting in 25 ml, as per manufacturer’s
instructions.
4. Gag-Protease-Reverse Transcriptase (GPRT)
amplification and sequencing
Samples were analysed in a two-step approach. First, an RT-
PCR amplification protocol [14] was used to amplify a 1.5 kb pol
fragment. This is later referred to as protocol 1. The resulting
HIV-1 genotype was used to select for resistant samples for this
study. Secondly, a 1.9 kb GPRT fragment was amplified (One-
Step SuperscriptIII High Fidelity, Invitrogen, CA, USA) using the
‘‘39-RT’’ and ‘‘59-OUT’’ primers [13], with a 10 ml RNA input in
a total volume of 35 ml. Nested PCR was performed using the
Expand High Fidelity PCR System (Roche Diagnostics GmbH,
Manheim, Germany), with 8 ml of first round amplicon and
primers 39IN, and 59IN in a final volume of 100 ml [13] resulting
in a final amplicon encompassing nucleotides 2012 to 3879 in pol
(according to HXB2 numbering – genbank: AF033829). This
second protocol is further referred to as protocol 2. Amplification
products were analyzed by 1% agarose gel electrophoresis, and
amplicons were purified using the QIAquick PCR Purification Kit
(Qiagen, Hilden, Germany) following manufacturer’s instructions.
Sequencing was performed using the Big Dye Terminator Cycle
Sequencing Kit v3.1 (Applied Biosystems, CA, USA) as described
previously [13]. Cycle sequencing purification was performed
using the DyeEX (Qiagen, Hilden, Germany) purification kit,
according to manufacturer guidelines. The ABI3730 XL (Applied
Biosystems, CA, USA) performed the sequence detection and
analysis was performed using the Sequencher v.4.5 software (Gene
Codes Corporation, MI, USA).
5. Genotypic Analysis
Sequence data generated from first-step analysis was submitted
to the Stanford University HIV drug resistance database [16] to
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the ARV drug resistance profiles, resistant samples were selected
for the GPRT amplification, and subsequent phenotypic drug
resistance analysis. The second-step (GPRT amplicon) sequence
data was submitted to the Stanford University HIV drug resistance
database.
6. In vitro phenotypic ARV drug resistance analysis
Recombinant virus stocks (RVS) were generated through
homologous recombination of each of the GPRT amplicons into
subtype B- and subtype C- backbones for use in the AntivirogramH
assay, as described by Hertogs et al. (1998) [12]. Generation of the
subtype C recombinant viruses was performed in MT4/eGFP cells
[13], whereas subtype B recombinant viruses were generated in
MT4 cell lines, respectively using eGFP expression and Cytopathic
Effect (CPE) scoring, respectively to monitor adequate viral
growth. One hundred (100) ml of harvested subtype B and C
recombinant viruses were then titrated in MT4/eGFP cells. A
panel of 18 ARV drugs (see below) was used in the antiviral
experiment to establish the resistance profile of the RVS.
Each GPRT amplicon was initially used to generate a full
subtype C recombinant virus (RVS_C) which was phenotyped in
the AntivirogramH assay. After phenotyping, the GPRT region of
the recombinant subtype C- backbone virus was PCR amplified as
described above, and the resulting amplicon was genotyped and
used to generate a recombinant subtype B- backbone virus. The
recombinant subtype B- backbone virus (RVS_B) was subsequent-
ly phenotyped, followed by PCR amplification and genotyping of
the GPRT region. The genotyping of the GPRT region was
performed at all three time points (plasma, RVS-C and RVS-B) to
ensure that the genetic background of the recombinant viruses was
identical throughout the phenotyping experiments (Figure 1). This
strategy was undertaken to first phenotype in a C-backbone
because C-backbone phenotyping took 10 to 23 days to harvest
virus, whilst only 5 to 10 days in a B-backbone. During this
extended time to harvest with the C-backbone, it was a concern
that there may have been some significant viral evolution during
that time, therefore the RVS_C that was harvested was used as
input into the B-backbone phenotyping.
Wild type subtype B (HXB2) and C [13] cell line adapted
viruses were used as reference viruses for the subtype B- and C-
backbone experiments, respectively. All 50% inhibitory concen-
tration (IC50) values were calculated from 8 readings for each
recombinant virus against the different ARV drugs. Fold changes
(FC) were calculated by dividing these IC50 values by the IC50 of
the appropriate reference virus. Viruses were characterized as
being susceptible or resistant based on pre-established biological
cut-off values (BCOs) [17].
ARV drugs and drug concentrations (mM) used in the antiviral
experiment included lamivudine (3TC; 0.12 to 31.25), zidovudine
(AZT; 4.88 10
23 to 1.25), stavudine (D4T; 0.24 to 62.50),
didanosine (DDI; 0.24 to 62.5), abacavir (ABC; 0.49 to 125),
emtricitabine (FTC; 7.63 10
24 to 5.00), tenofovir (TDF; 0.12 to
31.25), nevirapine (NVP; 4.88 10
23 to 1.25), efavirenz (EFV; 1.53
10
24 to 10.00), etravirine (ETR; 3.82 10
25 to 2.50), indinavir
(IDV; 4.88 10
23 to 1.25), fosamprenavir (APV; 4.88 10
23 to 1.25),
atazanavir (ATV; 0.48 10
25 to 0.31), saquinavir (SQV; 0.48 10
25
to 0.31), darunavir (DRV; 3.82 10
25 to 2.50), lopinavir (LPV; 0.24
10
25 to 0.16), and tipranavir (TPV; 0.02 to 5.00).
7. Statistical Analysis
Possible inter-batch IC50 differences between the wild-type
viruses, HXB2 and wildtype C were investigated for each ARV by
means of an analysis of variance (ANOVA). This was done by
comparing the IC50’s of all drugs repeatedly tested throughout 10
batches of experiments.
The comparison of resistance and susceptibility call rates
between the B- and C-backbone phenotyping were assessed by
calculating the sensitivity and specificity of the C-backbone
phenotype as compared to the B-backbone phenotype (regarded
as the gold standard). Sensitivity was calculated as (true sensitive/
(true sensitive + false resistant)6100) and specificity was calculated
as (true resistant/(true resistant + false sensitive)6100). Hence,
sensitivity measures the proportion of sensitive calls, which are
correctly identified, while specificity measures the proportion of
resistant calls, which are correctly identified.
Fold Change comparisons for which a discordant resistance call
was observed between B-backbone and C-backbone were further
assessed within the context of the intra-assay variability. Initially,
all FC values were ‘‘normalized’’ against BCO’s for the various
drugs, by subtracting the relevant ARV’s BCO from that FC
value. Hence, all FC values, regardless of the ARV that was tested,
could be compared collectively. FC values that gave the same
resistance call, regardless of their backbone of descent were
subtracted and used to set the acceptable FC variability limits
between both backbones. The mean +/22 standard deviations
(2SD) was calculated for the concordant FC comparisons
(susceptible and resistant viruses separately). The difference of
log FC values of the discordant data points were calculated, and
plotted on a Bland-Altman plot using the mean +/22SD derived
from the concordant samples as cut-offs. Any values outside these
cut-offs were considered to not fall within these acceptable limits of
assay variation, and hence truly discordant data points.
In addition, the capacity of the two backbones to detect
resistance caused by predominant subtype C ARV drug resistance
associated mutations was also assessed using Receiver of Operator
Characteristics (ROC) [18].
Results
1. Generating recombinant virus stocks from subtype C-
and B- viruses
A total of 265 clinical isolates were available for testing, 215
from ARV experienced patients, and 50 from therapy naı ¨ve
patients. In the protocol 2 amplification procedure [13], 237
GPRT amplicon were obtained, 190 and 47 from treatment-
experienced and naı ¨ve patients respectively. The 237 GPRT
amplicons were used to generate 132 subtype-C recombinant virus
stocks (RVS-C), which were subsequently GPRT amplified, and
recombined with a subtype B- backbone. One-hundred and
fourteen (114) subtype B RVS were generated. These RVS were
GPRT sequenced and compared. Only RSV-C and RSV-B
strains with identical genotypic analysis were included in further
analysis. Finally, 114 paired B- and C- backbone recombinant
viruses (78 from treatment-exposed +36 from treatment-naive)
were retained for further analysis. The process flow phenotypic
testing is given in Figure 1.
2. Genotypic analysis of the 114 sequences
The HIV-1 drug resistance mutation profiles [19] for the
treatment-exposed group (n=78) were analyzed. The most
prevalent mutations in this dataset included: K103N (n=30;
38.5%), M184V (n=26; 33.3%), T215Y (n=13; 16.7%), T215F
(n=8; 10.3%), M41L (n=9; 11.5%), V106M (n=8; 10.3%),
D67N (n=9; 11.5%), V108I (n=8; 10.3%). The treatment naı ¨ve
group (n=36) had no ARV drug resistance mutations.
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phenotypic testing
Prior to the IC 50 –values determination of the 114 RVS-C and
RVS-B preparations, assay variability for the subtype C
AntivirogramH assay was determined. The wild-type virus IC50
values were compared over the course of all experiment batches
(n=10) performed and for each drug tested, to determine assay
variability. No difference in the variance of the IC50 –values of the
wild-type viruses was noted amongst all drugs tested for the 10
experiments performed (p=0.41).
4. Analysis of the phenotypic resistance determinations
on 114 RVS-B and RVS-C strains
FC calculations, using respective wild-type viruses, were
performed to determine whether an RVS was sensitive or
resistant to a specific ARV. A summary of the subtype B- and C-
backbone phenotyping resistance profiles is shown in Table 1.
Not all 114 paired comparisons were obtained for every ARV.
For example, for AZT a total of 82 of the expected 114
comparisons were obtained, resulting in an AVE success rate of
71.9% for AZT. Using the AntivirogramH BCO’s [17], the FC
values for the RVS-B (gold standard) were designated as being
either sensitive (n=1272) or resistant (n=378) to a particular
A R V .U s i n gt h es a m eB C O ’ sa sf o rt h eB -b a c k b o n e ,t h eC -
backbone phenotype resistance calls were determined as
sensitive (n=1192) and resistant (n=458). A total of 1650
paired subtype B- and C- backbone derived FC comparisons
were obtained, with an overall AVE success rate for all drugs of
85.1%.
Resistance and susceptibility call rates were compared to obtain
sensitivities and specificities of the C- backbone phenotyping
(Table 1). Sensitivity ranged from 69.9% to 89.9% (overall mean
87.5%), and specificity from 20.0% to 100.0% (overall mean
72.4%). A low sensitivity depicts that the C- backbone is over-
calling resistance, and a low specificity means that the C-
backbone is under-calling resistance. The observed resistance call
discordances were further assessed for their relationship to
genotypic predictions (Table 2), and biological variation, which
may affect resistance calling in those samples with FC values close
to the BCO (Figure 2).
5. Concordance and discordance analysis
The concordant and discordant data points are summarized in
Table 2. Firstly, 1118 data points were called sensitive and 304
called resistant in both backbones. This resulted in 86.2% (1422/
1650) concordant data points. Secondly, comparisons which were
sensitive in the B- backbone and resistant in the C- backbone
(B’sens/C’res) (n=154) were 58.4% (90/154) concordant with a
sensitive genotypic call in the genotypic interpretations from the
Stanford HIV Drug Resistance database [16]. The comparisons
which were resistant in the B- backbone and sensitive in the C-
backbone (B’res/C’sens) were 16.2% (12/74) concordant with a
resistant genotypic interpretation.
6. Analysis of the observed variability of FC values
between backbones
To ascertain the acceptable variability of FC values generated in
both backbones, the mean FC difference +/22SD of the
Figure 1. Process flow diagram for phenotyping procedure within subtype B- and C- backbones.
doi:10.1371/journal.pone.0034708.g001
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Altman plot, to visualize truly discordant B- and C- backbone
comparisons, with the log FC of B- backbone derived data on the
x-axis, and the difference between the B- and C- backbone derived
log FC’s on the y-axis (Figure 2). Under these settings, 95.8% (i.e.
1590 from 1660 comparisons) of the phenotypic data derived from
subtype B- backbone viruses had a concordant resistance call with
subtype C- backbone derived data. Sixty-three (63) and 7 data
points lie outside of the mean 6 2SD for the B’sens/C’res
(Figure 2A) and B’res/C’sens (Figure 2B) data, respectively.
Collectively, these 70 data points were considered discordant data
points. The 70 discordant comparisons were predominantly from
samples with a resistant genotype, who were treatment experi-
enced (60/70), with 10 out of the 70 being from sensitive and
treatment naı ¨ve samples.
7. ROC curves
Finally, the capacity of the different backbone phenotyping to
predict ARV drug resistance associated with the M184V, K103N
and V106M mutations was assessed. Only these 3 mutations were
assessed, as other mutations in this sample set had too few
observations for meaningful data interpretation. Table 3 summa-
rizes ROC curve analyses, which demonstrates the tradeoff
between sensitivity and specificity for the subtype B- and C-
backbone based phenotyping assays in detecting decreased
sensitivity caused by M184V, K103N and V106M mutations.
The tests of differences between the areas under the empiric ROC
curves show that regardless of the range of BCOs, the two
backbones report the same detection sensitivities for ARV drug
resistance to these 3 mutations.
Discussion
The emergence of ARV drug resistance in HIV-1 infected
patients requires that clinicians make informed decisions when
selecting the next ARV regimen based on genotypic and/or
phenotypic drug resistance testing. However, based on its cost and
logistic requirements, genotyping may not yet be an HIV-1 drug
resistance monitoring tool in resource limited settings. Nonethe-
less, this methodology can certainly be used in monitoring HIV
resistance on a population-based level at selected sites in Africa.
The current study is primarily meant to ensure that the genotyping
data generated through such monitoring programs for Africa are
supported by phenotyping as a gold standard. This study evaluated
the feasibility of using a phenotypic assay (AntivirogramH) based
on a subtype B- backbone for resistance testing of subtype C
infected patient samples.
Choe et al. (2007) [20] reported that the interpretation of ARV
drug susceptibility using the PhenosenseH phenotypic assay was
not dependent on the subtype of the backbone vector (B vs. C).
Furthermore, comparative analyses of commercially available
Table 1. Comparison between HIV-1 subtype B and C backbone phenotyping resistance profiles.
ARV
BCO
(FC)
AVE success
rate (%) B Backbone Phenotype C Backbone Phenotype
Total paired
Comparisons
(n)
SENSITIVITY
(%)
SPECIFICITY
(%)
SENSITIVE (n) RESISTANT (n) SENSITIVE (n) RESISTANT (n)
AZT 2.5 71.9 74 8 72 10 82 97.3 100.0
3TC 2.1 76.3 45 42 51 36 87 91.1 76.2
DDI 2.3 95.6 73 36 61 48 109 69.9 72.2
D4T 2.2 79.8 89 2 82 9 91 92.1 100.0
ABC 2.3 96.5 80 30 66 44 110 78.8 90.0
FTC 3.1 85.1 52 45 46 51 97 84.6 95.6
TFV 2.2 96.5 101 9 89 21 110 83.2 44.4
NRTI 86.0 514 172 467 219 686 85.3 82.6
NVP 6.0 93.0 52 54 46 60 106 86.5 98.1
EFV 3.3 85.1 42 55 36 61 97 81.0 96.4
ETR 3.2 86.8 79 20 67 32 99 77.2 70.0
NNRTI 88.3 173 129 149 153 302 81.6 88.2
IDV 2.3 74.6 76 9 77 8 85 98.7 77.8
SQV 1.8 74.6 82 3 77 8 85 92.7 66.7
APV 2.2 89.5 90 12 93 9 102 98.9 66.7
LPV 1.6 81.6 73 20 68 25 93 78.1 45.0
ATV 2.1 86.0 86 12 82 16 98 91.9 75.0
TPV 1.7 96.5 94 16 96 14 110 91.5 37.5
DRV 2.0 78.1 84 5 83 6 89 94.0 20.0
PI 83.0 585 77 576 86 662 92.3 55.5
All_Drugs 85.1 1272 378 1192 458 1650 87.5 72.4
ARV abbreviation: lamivudine(3TC), zidovudine (AZT), stavudine (D4T), didanosine (DDI), abacavir (ABC), emtricitabine (FTC), tenofovir (TFV), nevirapine (NVP), efavirenz
(EFV), etravirine (ETR), indinavir (IDV), fosamprenavir (APV), atazanavir (ATV), saquinavir (SQV), darunavir (DRV), lopinavir (LPV), tipronavir (TPV). Sensitivity was calculated
as (true sensitive/(true sensitive + false resistant)6100) and specificity was calculated as (true resistant/(true resistant + false sensitive)6100). BCO: Biological Cut-off.
AVE: Antiviral Experiment. FC: Fold Change.
doi:10.1371/journal.pone.0034708.t001
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the vircoHTYPE HIV-1 (virtualPhenotype) with PhenoSenseH
[22] found that results correlate well, despite the use of different
testing strategies. These two assays amplify the 39 part of gag,
including the p7/p1 and p1/p6 cleavage sites, the entire protease,
and most of RT (AntivirogramH: RT amino acids 1–400 and
PhenoSenseH: RT amino acids 1–311) [12]; [23]. With the
minor difference in the length of RT sequence (aa 311–400) used
in these two assays, it is thus expected that the subtype of the
backbone used in the AntivirogramH assay should also not
impact on the interpretation of ARV drug susceptibility of non-B
subtypes. Although the IAS guidelines [19] suggest that no
known resistance mutations appear between amino acids 311
and 400, the vircoHTYPE HIV-1 algorithm [24] and the
Stanford University drug resistance database [16] have listings
of resistance mutations within this region. No difference in these
assays are expected, however, since Steegen et al. [24] showed
that using a shortened RT sequence (aa41–238) for genotyping,
still gave comparable genotypic resistance results as sequencing a
full RT.
Figure 2. Plots showing discordant phenotypic resistance comparisons, and variation around the BCO. The FC of the B backbone
derived viruses (assumed to be the gold standard) are shown on the x-axis, and the difference in log FC values (B backbone FC – C backbone FC) on
the y-axis. The shaded region on the plots is the region wherein the log FC biological cut-offs lie for the 18 ARVs tested. The mean +2SD and mean
22SD are drawn in to illustrate the natural variation around the BCO. Any point s found above the mean +2SD or below the mean 22SD are
considered to be truly discordant. Figure 2A is a plot of comparisons within the B’sens/C’res group. Figure 2B is a plot of comparisons within the
B’res/C’sens group.
doi:10.1371/journal.pone.0034708.g002
Table 2. Stanford University HIV Drug Resistance Database Resistance Profiles of Phenotypic Comparisons.
Phenotype
category Stanford HIVdb ARV Drug Resistance Profiles
Total (n)
Sensitive + Potential
Low Resistance (n)
Low
Level Resistance (n)
Intermediate
Level Resistance (n)
High
Level Resistance (n)
B’sens/C’sens{ 1118 NP NP NP NP
B’res/C’res{ 304 NP NP NP NP
B’sens/C’res* 154 90 25 25 14
B’res/C’sens** 74 62 6 6 0
NP: Comparison not performed
Stanford HIVdb genotypic data not shown for concordant comparison, as this was only done to try ascertain if one backbone’s phenotype was consistently miscalling
(with reference to genotype).
{B’sens/C’sens are those comparisons which were sensitive in both the B and C backbone.
{B’res/C’res{are those comparisons which were resistant in both the B and C backbone.
*B’sens/C’res are those comparisons which were sensitive in the B backbone and resistant in the C backbone.
**B’res/C’sens are those comparisons which were resistant in the B backbone and sensitive in the C backbone.
doi:10.1371/journal.pone.0034708.t002
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necessary for recombination with the AntivirogramH subtype B-
and C- backbone [13]. Unlike Nauwelaers et al. (2011) [13], who
used a clonal phenotyping approach, this work used population-
based phenotyping, which depicts what would happen in a clinical
setting. This population-based approach is preferred due to ease of
use in comparison to the clonal approach.
Of the 133 amplicons initially phenotyped in a C- backbone,
114 paired subtype B and C phenotypes were obtained. During
the phenotyping process, some of the transfections failed to yield
recombinant viruses especially in the C- backbone. Often it was
noted that even though adequate virus was scored with eGFP
scoring for the C- backbone, when titrated, the desired yield of
virus was not obtained. The standard CPE scoring is not an option
for C-backbone viruses, as subtype C viruses do not produce CPE
in these cell types [25], [13], and therefore other alternatives were
required (eg. eGFP scoring using MT4/EGFP cells). A suggestion
is that a more direct measurement of virus concentration should be
used for the scoring of these viruses (eg. p24).
With 114 paired B- and C-phenotype comparisons, and 17
drugs tested, the expected number of FC comparisons would be
1938. Only 1650 comparisons were obtained however, with an
overall AVE success rate of 85.1%. A lowered AVE success rate
was generally noted to be a result of failure to meet the quality
control criteria set for AntivirogramH analyses of either a B- or C-
backbone derived IC50 reading. Fluorescent pixel intensity
readings for subtype C- backbone derived viruses were often too
high for accurate IC50 calculations to be made. This could be
attributed to the different scoring method used for C-backbone
viruses or altered replication capacities of the different virus
subtypes, but was not investigated further in this study.
Resistance and susceptibility calls were compared between the
phenotypes derived from the two backbones, as one of the primary
objectives of the study was to analyze the concordance of results by
phenotypic category because of the direct implications for patient
management. Sensitivity and specificity was calculated for each
ARV drug tested, using the subtype B- backbone as the gold
standard, and hence subtype B derived BCO’s as the ubiquitous
cut-offs. An 87.9% (average sensitivity) of susceptible calls
(FC,BCO) were correctly identified in the C- backbone. For
some drugs, like ddI, ABC, ETR and APV, with sensitivities of less
than 80%, it appears that the C- backbone is over-reading
resistance as compared to B-backbone results. In terms of
specificity, a 72.4% average is noted overall, with markedly low
specificities observed within the PI group. The interpretation of
which, is that there is some over-calling of resistance occurring in
the B- backbone, particularly within the PI group. This may be a
result of there being an insufficient amount of data illustrating
HIV-1 subtype C drug resistance to PIs in this study, as PIs are
mainly part of the second-line regimen in South Africa, which has
resulted in few patients developing PI resistance.
A high number of concordant resistance calls were reported,
with 1118 comparisons within the B’sens/C’sens category, and
304 within the B’res/C’res category, thus accounting for 86.2%
(1422/1650) of comparisons tested. The discordant resistance calls
resulting were compared with genotypic profiles as per the
Stanford University drug resistance database [16] to investigate
which backbone is theoretically giving the correct call (Table 2).
Ultimately, subtype B backbone phenotyping was being assessed
for use with subtype C specimens. In the following discordant B-
and C-backbone resistant calls, a comparison was made of how the
B-backbone resistance calls fare with a genotypic algorithm. Data
shows that for discordant comparisons, the sensitive B- backbone
phenotype agreed with genotypic sensitive calls for 58.4% (5.5%
(90/1650) of resistance over-calling) of these cases, and only 16.2%
of resistant B- backbone phenotype corresponded to the resistant
genotype. The implications of the 16.2% correct calling of
resistance in the B backbone was that, in terms of the genotypic
prediction algorithm the B- backbone had a 0.7% rate of under-
calling resistance in these particular cases. Notably, these
discordant samples only account for 13.8% (228/1650) of total
comparisons made. These discordant comparisons were quite
diverse, with no trends being noted in terms of resistance
mutations and/or ARV resistance profiles affected, hence results
could not be further elaborated upon. Nonetheless, the clinical
implications of the under-calling of resistance would be that
patients would remain on a failing drug regimen whilst
accumulating more resistance. The over-calling of resistance
would mean that patients would be switched too early onto
second-line regimens.
Restrictions encountered with these analyses are that only
subtype B derived BCO’s are available, and these discrepancies
may be a result of using inappropriate BCO’s for subtype C-
backbone viruses. The above analyses are also reliant on a single
BCO value, not taking into account any variation around that cut-
off nor of the assay variation. If a subtype-specific C-backbone is to
be used, it would need to be investigated whether subtype-specific
BCO’s would need to be derived. Phenotypic output throughout
various assays is shown to have expected inter- and intra- assay
variability due to the nature of this in vitro assay [20,21,26,27]. By
indirectly taking these confounding factors into account (i.e.
Figure 2), the truly discordant comparisons were targeted (outside
the mean +/22SD range). Collectively, it was calculated that
95.8% (1590/1660) of all phenotypic data derived from the
Table 3. Receiver of Operator Characteristic (ROC) statistics for 3 common HIV-1 subtype C resistance mutations.
Resistance Mutation Antiretroviral Drug Number of Observations ROC Curve Statistics
With
resistance mutation
Without any
resistance mutations
Difference
(B–C) CI P-value
M184V 3TC 27 33 0.01 20.21, 0.18 0.896
FTC 39 27 0.02 20.05, 0.01 0.218
K103N NVP 37 31 0.01 20.04, 0.01 0.278
EFV 34 29 0.0009 20.003, 0.001 0.480
V106M NVP 14 31 0.14 20.39, 0.11 0.272
EFV 12 29 0.17 20.43, 0.08 0.187
doi:10.1371/journal.pone.0034708.t003
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that of the subtype C- backbone derived viruses. Of the 70
discordant values found, only 10 comparisons were from treatment
naı ¨ve (sensitive virus as per Stanford drug resistance database
predictions), re-iterating that the B- and C- backbone assay
variability is similar. Similar results were noted in a study by Choe
et al. (2007) [20], who performed an analogous experiment within
the PhenoSenseH assay, showing a concordance of 95.8% of pair
wise FC value comparisons across all drugs for all subtype C
viruses tested in B- and C- backbone.
Another minor restriction of this analysis is that the majority of
recombinant viruses carried the M184V, the K103N and the
V106M mutations, which provide high-level resistance to 3TC
and FTC with M184V or EFV and NVP with K103N and
V106M. The virus backbone in such cases may theoretically have
a decreased, if any, impact on the phenotypic result. In the context
of the sample set used in this analysis, the prevalence of other
mutations considered to not be classed as high-level resistance
were not present in high amounts, and as such this could not be
further studied.
An assessment of the sensitivities of these two backbones to
measuring resistance in the presence of the M184V, K103N, or
V106M mutation was performed. These particular mutations were
selected for this analysis, in the context that subtype C viruses are
under investigation in these experiments, and these mutations
have previously been shown to be some of the most prevalent drug
resistance mutations in subtype C treatment failures [10]. It would
have been of interest to look at the K65R and thymidine analogue
mutations (TAMs), but there were insufficient data points available
for appropriate ROC analysis to be performed. ROC curves were
plotted (data shown in Table 3), and no statistical differences noted
with any of these 3 mutations. The detection sensitivity of both
backbones was equal in measuring resistance to these prominent
drug resistance mutations.
No systematic resistance under- or overcalling of the subtype C
amplicons in the B- backbone phenotyping was noted. It appears
that the virus backbone susceptibility outside of the GPRT region
does not contribute to any changes in phenotypic FC values. The
practical question being considered in this work is whether or not
it is reliable to use a subtype B- backbone (as is currently the case
with all available phenotypic assays) when assessing HIV-1 subtype
C. In clinical practice, what this data suggests is that in the
instance of subtype C, it is reliable for 95.8% of cases to use a B-
backbone for phenotyping, once assay variability is to taken into
account. Assay variability is especially important when FC values
are close to the BCO’s. Clinical decisions should not only be made
merely according to the resistance call, but rather actual FC values
should be considered. Caution should also be taken even when
assessing resistance of non-B subtypes in a subtype B- backbone.
This study indirectly suggests that the vircotype tool, which is built
upon the Antivirogram database, is an equally reliable algorithm
for genotyping subtype C samples. The AntivirogramH assay
therefore remains an acceptable tool for phenotyping non-B
GPRT amplicons.
Acknowledgments
The authors acknowledge the staff at Virco, who trained and assisted with
the phenotyping process, and phenotypic data analysis: Peggy van den
Zegel, Maxine Feyaerts, Rein de Vos, Kelly Aerts, Elfi de Haes, Kelly
Heyns, Ilse Hofmans, An Verheyen and Ilse Andries. We also thank
PASER principal investigators for granting permission to use PASER-M
baseline samples for the treatment-naı ¨ve sample group, and ART-A
Consortium Partners: Contract Laboratory Services (CLS) – South Africa;
Center for Poverty-related Communicable Diseases, Academic Medical
Centre, University of Amsterdam; Centre de Recherche Public de la Sante
(CRP-Sante); PharmAccess Foundation, Amsterdam, The Netherlands;
University Medical Centre Utrecht (UMCU) – Department of Virology;
Virco BVBA; Wits Health Consortium (WHC).
Author Contributions
Conceived and designed the experiments: MB KS CLW WSS TRDW
LJS. Performed the experiments: MB KS. Analyzed the data: MB KS
HDW MVH LJS. Contributed reagents/materials/analysis tools: LJS WSS
CLW. Wrote the paper: MB KS MAP LJS. Provided significant comments
and editing on the paper: CLW HDW MVH WSS TRDW.
References
1. WHO, UNICEF, UNAIDS (2010) Towards universal access. Scaling up priority
HIV/AIDS interventions in the health sector. Geneva, World Health
Organization. Available:http://www.who.int/hiv/pub/2010progressreport/
full_report_en.pdf. Accessed 28 May 2011.
2. Hamers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit TR, et al.
(2008) The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan
Africa. Antiviral Therapy 13: 625–639.
3. Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, et al. (2011) HIV-1
drug resistance at antiretroviral treatment initiation in children previously
exposed to single-dose nevirapine. AIDS Jul 31;25: 1461–1469.
4. Price M, Wallis C, Lakhi S, Karita E, Kamali A, et al. (2011) Transmitted HIV
type 1 drug resistance among individuals with recent HIV infection in East and
Southern Africa. AIDS Res Hum Retroviruses Jan 27: 5–12.
5. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, et al. (2011) HIV-1
drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after
rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect
Dis Jul. 27 p.
6. Hamers RL, Siwale M, Wallis CL, Labib M, van Hasselt R, et al. (2010) HIV-1
drug resistance mutations are present in six percent of persons initiating
antiretroviral therapy in Lusaka, Zambia. Journal of acquired immune
deficiency syndromes (1999) 55: 95–101. Available:http://www.ncbi.nlm.nih.
gov/pubmed/20585262.
7. Ndembi N, Hamers R, Sigaloff K, Lyagoba F, Magambo B, et al. (2011)
Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young
individuals in Kampala. AIDS Apr 24; 25: 905–910.
8. Hemelaar J, Gouws E, Ghys PD, Osmanov S (2011) Global trends in molecular
epidemiology of HIV-1 during 2000–2007. AIDS Mar 13; 25: 679–689.
doi:10.1097/QAD.0b013e328342ff93.
9. VanZyl G, VanderMerwe L, Claassen M, Zeier M, Preiser W (2011)
Antiretroviral resistance patterns and factors associated with resistance in adult
patients failing NNRTI-based regimens in the western cape, South Africa. J Med
Virol Oct; 83: 1764–1769.
10. Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, et al. (2010) Outcomes after
virologic failure of first-line ART in South Africa. AIDS 24: 1007–1012.
11. Virco BVBA (n.d.) Belgium. Available:http://www.vircolab.com/hiv-resistance-
products/antivirogram. Accessed 2 March 2011.
12. Hertogs K, de Be ´thune M, Miller V, Ivens T, Schel P, et al. (1998) A rapid
method for simultaneous detection of phenotypic resistance to inhibitors of
protease and reverse transcriptase in recombinant human immunodeficiency
virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob
Agents Chemother Feb 42: 269–276.
13. Nauwelaers D, Houtte MV, Winters B, Steegen K, Baelen KV, et al. (2011) A
Synthetic HIV-1 Subtype C Backbone Generates Comparable PR and RT
Resistance Profiles to a Subtype B Backbone in a Recombinant Virus Assay.
PLoS ONE May 6: e19643. doi:10.1371/journal.pone.0019643.
14. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kaleebu P, et al. (2010)
Affordable in-house antiretroviral drug resistance assay with good performance
in non-subtype B HIV-1. Journal of Virological Methods 163: 505–508.
doi:10.1016/j.jviromet.2009.11.011.Affordable.
15. Hamers R, Oyomopito R, Kityo C, Phanuphak P, Siwale M, et al. (2011)
Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia
(TASER-M) Monitoring Studies to Evaluate Resistance-HIV drug resistance in
sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol Apr 21.
16. Rhee S-J, Gonzales M, Kantor R, Betts B, Ravela J, et al. (2003) Human
immunodeficiency virus reverse transcriptase and protease sequence database.
Nucleic Acids Research 31: 298–303.
17. Virco B (n.d.) Virco Biological Cut-offs. Available:http://www.vircolab.com/
hiv-resistance-products/vircotype-hiv-1/cut-offs-for-vircotype-hiv-1/biological-
cut-offs. Accessed 5 June 2010.
HIV-1 Resistance Testing Is Subtype Independent
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e3470818. Vergara IA, Norambuena T, Ferrada E, Slater AW, Melo F (2008) StAR: a
simple tool for the statistical comparison of ROC curves. BMC Bioinformatics 9:
265. Available:http://protein.bio.puc.cl/star.html. Accessed 12 May 2011.
19. Johnson VA, Brun-Ve ´zinet F, Clotet B, Gu ¨nthard HF, Kuritzkes DR, et al.
(2010) Update of the drug resistance mutations in HIV-1: December 2010.
Topics in HIV medicine : a publication of the International AIDS Society, USA
18: 156–163. Available:http://www.ncbi.nlm.nih.gov/pubmed/21245516.
20. Choe S, Stawiski E, Parkin N (n.d.) Interpretation of Drug Susceptibility and
Replication Capacity Results from Subtype C HIV-1 Protease/RT Is Not
Influenced by the Subtype of the Resistance Test Vector. XV International HIV
Drug Resistance Workshop Bridgetown, Barbados.
21. Qari SH, Respess R, Weinstock H, Beltrami EM, Hertogs K, et al. (2002)
Comparative Analysis of Two Commercial Phenotypic Assays for Drug
Susceptibility Testing of Human Immunodeficiency Virus Type 1. J Clin
Microbiol 40: 31–35. doi:10.1128/JCM.40.1.31.
22. VanHoutte M, Picchio G, Van Der Borght K, Pattery T, Lecocq P, et al. (2009)
A comparison of HIV-1 drug susceptibility as provided by conventional
phenotyping and by a phenotype prediction tool based on viral genotype. J Med
Virol Oct 81: 1702–1709.
23. Petropoulos C, Parkin N, Limoli K, Lie Y, Wrin T, et al. (2000) A novel
phenotypic drug susceptibility assay for human immunodeficiency virus type 1.
Antimicrob Agents Chemother Apr 44: 920–928.
24. Steegen K, Bronze M, Van Craenenbroeck E, Winters B, Van der Borght K,
et al. (2010) A comparative analysis of HIV drug resistance interpretation based
on short reverse transcriptase sequences versus full sequences. AIDS Res Ther
Oct 15: 38.
25. Arie ¨n K, Abraha A, Quin ˜ones-Mateu M, Kestens L, Vanham G, et al. (2005)
The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1)
group M, HIV-1 group O, and HIV-2 isolates. J Virol Jul 79: 8979–8990.
26. Wang K, Samudrala R, Mittler JE (2004) Antivirogram or PhenoSense: a
comparison of their reproducibility and an analysis of their correlation. Antiviral
Therapy Oct 9: 703–712.
27. Zhang J, Rhee S, Taylor J, Shafer RW (2005) Comparison of the Precision and
Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays.
J Acquir Immune Defic Syndr 38: 439–444.
HIV-1 Resistance Testing Is Subtype Independent
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e34708